Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.
Actively Recruiting
Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.
Actively Recruiting
Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in Chinese patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have HER2 mutations. Although T-DXd is approved and has shown efficacy in clinical trials for NSCLC patients with these mutations, there is limited data on its use outside clinical trial settings in China. This is a non-interventional, observational study where no study drug will be provided or administered by the study team. Participants who have already received T-DXd as part of their routine care, based on their physicians decision, will be enrolled and observed. The study focuses on patients receiving T-DXd as at least a second-line treatment. Participants will be followed for up to approximately two years, during which researchers will collect information on progression-free survival, overall survival, treatment responses, and any treatment-related side effects. Data collection will include assessments by investigators and monitoring of adverse events to evaluate safety and tolerability in a real-world setting.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two different treatment regimens to eradicate Helicobacter pylori infection. This trial compares a dual therapy using linralase glutarate capsules combined with amoxicillin against a quadruple therapy that includes bismuth. The main goal is to see if the dual therapy is not less effective than the quadruple therapy, while also monitoring patient adherence and side effects. This is a phase 4, randomized, open-label study aimed at first-line treatment of this infection. Participants receive either the dual-drug regimen of linralase glutarate capsules 50 mg twice daily plus amoxicillin 1 g three times daily or the quadruple therapy consisting of esomeprazole 20 mg twice daily, clarithromycin 0.5 g twice daily, amoxicillin 1 g twice daily, and colloidal bismuth subcitrate 200 mg twice daily. Both treatment courses last for 14 days. The study groups are assigned randomly and monitored during and after treatment to assess outcomes. During the study, participants undergo testing to determine the Helicobacter pylori eradication rate 28 days after treatment ends. Researchers also track adverse events during the 14 days of treatment and for 28 days following treatment completion. Participants adherence to the medication regimens is evaluated throughout. The trial includes adults aged 18 to 70 years who meet specific diagnostic and health criteria. The total duration from treatment to outcome measurement spans about 6 weeks, including follow-up assessments.
Actively Recruiting
Researchers are evaluating a machine learning model that predicts cycloplegic refraction in adults with myopia using standard non-cycloplegic eye measurements. The goal is to reduce the use of cycloplegic drops, which are time-consuming and cause discomfort, while still identifying patients who need them. This approach addresses the challenge that non-cycloplegic measurements alone cannot reliably identify those at risk of overcorrection. The study includes adult myopes who undergo routine cycloplegic refraction with tropicamide. Participants are grouped based on the difference between their non-cycloplegic and cycloplegic spherical equivalent measurements, with one group having a difference of 0.50 diopters or more, and the other less than 0.50 diopters. The machine learning model uses non-cycloplegic parameters to predict cycloplegic refractive error and is assessed for its diagnostic performance. Participants have non-cycloplegic and cycloplegic refractions performed within 7 days, along with detailed eye measurements. Researchers evaluate the accuracy of the models predictions compared to actual cycloplegic measurements on the same day. Outcomes include the models ability to identify patients needing cycloplegic refraction and agreement between predicted and measured values. The study lasts until November 2026, with assessments focused on day 0 measurements.
Actively Recruiting
Langerhans cell histiocytosis LCH is a disorder mostly affecting children, caused by an abnormal buildup of Langerhans cells in body tissues. This disease varies widely in severity, with mild cases often resolving on their own and severe multisystem cases involving multiple organs like liver, spleen, or bone marrow, which can be life-threatening without proper treatment. Standard treatment includes prednisone and vinblastine chemotherapy, but some children develop resistance or relapse, leading to long-term health problems. This trial studies whether adding a targeted drug called luvometinib to chemotherapy can improve outcomes in children with multisystem LCH. Participants will be randomly assigned to receive either a modified standard chemotherapy regimen prednisone and vincristine alone or the same chemotherapy combined with oral luvometinib, a MEK12 inhibitor taken daily. The chemotherapy also includes mercaptopurine during maintenance. The study is conducted at multiple centers and aims to evaluate if the combination treatment improves patient outcomes compared to chemotherapy alone. During the trial, children will be closely monitored through clinical and imaging evaluations. Researchers will assess event-free survival over two years, responses at 1 and 3 months after treatment, overall survival, and any treatment-related side effects. Follow-up will include safety assessments and regular check-ups to track disease progression and treatment tolerance throughout the study period.
Actively Recruiting
Researchers are studying MCLA-129, a human bispecific antibody targeting EGFR and cMet, in patients with advanced solid tumors, including non-small cell lung cancer NSCLC, head and neck cancer, and colorectal cancer. This multi-center, open-label Phase III study aims to evaluate the safety, pharmacokinetics, and antitumor activity of MCLA-129. The study includes patients with tumors that have progressed after standard treatments or are intolerant to them. The study has two parts Part I involves dose escalation and dose expansion to determine safe and effective dose levels of MCLA-129 administered by intravenous infusion every one or two weeks. Part II is a cohort expansion phase assessing efficacy, safety, and pharmacokinetics at the recommended Phase II dose in groups of patients with specific biomarker profiles, such as EGFR mutations or MET amplification. Participants will receive MCLA-129 infusions in 28-day cycles and undergo regular assessments including tumor measurements, safety monitoring, and pharmacokinetic testing. Primary outcomes include dose-limiting toxicity, maximum tolerated dose, overall response rate, and treatment-emergent adverse events. Secondary outcomes measure drug levels, response duration, progression-free survival, and overall survival. Follow-up continues for approximately two years after treatment initiation to monitor effects and safety.
Actively Recruiting
Researchers are comparing the study drug sacituzumab govitecan SG Trodelvy to standard treatments in people with extensive stage small cell lung cancer ES-SCLC who have already received prior therapy. The main goal is to see which treatment helps participants live longer by measuring overall survival. This is a global, randomized, open-label Phase 3 trial conducted to evaluate the effects of SG versus standard care in this patient population. Participants in the study are randomly assigned to one of two treatment groups. Group A receives sacituzumab govitecan intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle. Group B receives one of several approved standard treatments chosen by the investigator, including topotecan, lurbinectedin where available, or amrubicin in Japan, administered according to usual schedules in 21-day cycles. Treatment continues until disease worsens, unacceptable side effects occur, death, or other reasons for stopping treatment. During the study, participants undergo regular assessments including imaging scans to measure tumor response, physical evaluations, and laboratory tests to monitor safety. Researchers track important outcomes such as progression-free survival, response rates, duration of response, and quality of life measures related to breathing and physical function for up to 4.5 years. Safety is closely monitored by recording adverse events and laboratory abnormalities throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating a new way to improve the diagnosis and treatment of lung cancer by creating synthetic PET images from CT scans. This method aims to keep important biological details and add clinical value by linking anatomical CT images with metabolic PET scans. The study is observational and takes place across multiple centers to validate the usefulness of this approach for lung cancer patients. Participants will undergo paired diagnostic CT and FDG-PET scans as part of their routine clinical care, with the PET-CT scan performed before starting systemic treatment for the tumor. The study focuses on analyzing these imaging data to develop a model that maps anatomical details to metabolic activity, without adding extra treatment or interventions. During the study, researchers will measure how closely the synthetic PET images match the real ones using metrics like structural similarity, peak signal-to-noise ratio, and metabolic parameter consistency. They will also assess the predictive performance of the model. The study runs from December 2025 to December 2026, involving patients with non-small cell lung cancer who consent to participate and have both CT and FDG-PET scans available.
1-10 of 13
1